Who are Cisplatin + Gemcitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Platinum + Gemcitabine, Carboplatin + Gemcitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cisplatin-gemcitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cisplatin + Gemcitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cisplatin + Gemcitabine (Cisplatin + Gemcitabine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (platinum agent + nucleoside analog). Area: Oncology.

phase 3 Chemotherapy combination (platinum agent + nucleoside analog) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cisplatin + Gemcitabine (Cisplatin + Gemcitabine) — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Cisplatin and gemcitabine work together as a chemotherapy combination to damage cancer cell DNA and inhibit nucleotide synthesis, leading to cell death.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Cisplatin + Gemcitabine TARGET	Cisplatin + Gemcitabine	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	phase 3	Chemotherapy combination (platinum agent + nucleoside analog)
Platinum + Gemcitabine	Platinum + Gemcitabine	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Chemotherapy combination (platinum agent + nucleoside analog)	DNA (platinum crosslinking); ribonucleotide reductase and DNA polymerase (gemcitabine)
Carboplatin + Gemcitabine	Carboplatin + Gemcitabine	AstraZeneca	phase 3	Chemotherapy combination (platinum agent + nucleoside analog)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (platinum agent + nucleoside analog) class)

AstraZeneca · 1 drug in this class
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cisplatin + Gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-gemcitabine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing